Finerenone in Persons with Chronic Kidney Disease without Diabetes.

Publication Title

The New England journal of medicine

Authors

• Hiddo J L Heerspink
• Brendon L Neuen
• Rajiv Agarwal
• David Z I Cherney
• Carolyn S P Lam
• Katherine Tuttle, Providence Inland Northwest Health, University of Washington School of Medicine, Spokane.Follow
• Christoph Wanner
• Pantelis Sarafidis
• Niels Jongs
• J David Smeijer
• Meike Brinker
• Nicole Rethemeier
• Patrick Schloemer
• Paula Vesterinen
• David Goldsbury
• Sara Dizayee
• Jon W Mares
• Vlado Perkovic

Document Type

Article

Publication Date

6-4-2026

Keywords

washington; spokane

Abstract

BACKGROUND: In randomized trials, finerenone, a nonsteroidal mineralocorticoid receptor antagonist, improved kidney and cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease (CKD). Whether finerenone has similar effects in patients without diabetes who have CKD is unknown.

METHODS: We randomly assigned adults without diabetes who had CKD (estimated glomerular filtration rate [eGFR], 25 to < 90 ml per minute per 1.73 m

RESULTS: A total of 1584 participants underwent randomization - 793 were assigned to the finerenone group, and 791 to the placebo group. The mean (±SD) baseline eGFR was 46.8±16.2 ml per minute per 1.73 m

CONCLUSIONS: Among adults with CKD who did not have diabetes, finerenone led to a slower decrease in the eGFR than placebo over 32 months. (Funded by Bayer; FIND-CKD ClinicalTrials.gov number, NCT05047263.).

Area of Special Interest

Kidney & Diabetes

Specialty/Research Institute

Endocrinology

Specialty/Research Institute

Nephrology

Specialty/Research Institute

Pharmacy

DOI

10.1056/NEJMoa2604625